Valuation: Geron Corporation

Market Cap 949M 833M 776M 714M 1.34B 90.71B 1.36B 9.21B 3.6B 44.98B 3.56B 3.49B 155B P/E 2026 *
-92.5x
P/E 2027 * 16.4x
Enterprise Value 928M 815M 759M 698M 1.31B 88.7B 1.33B 9B 3.52B 43.99B 3.49B 3.41B 152B EV / Sales 2026 *
3.96x
EV / Sales 2027 * 2.28x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-1.69%
1 week+1.74%
Current month+14.45%
1 month+12.69%
3 months-2.98%
6 months+10.15%
Current year+10.98%
1 week 1.39
Extreme 1.3901
1.53
1 month 1.26
Extreme 1.26
1.62
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Free

Director

6,103 0.0010%
20/05/26 Free

Director

220,000 0.0343%
20/05/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-1.69%+1.74%+27.39%-53.93% 949M
-2.25%+1.55%+50.84%+70.04% 56.19B
-1.32%-0.97%+38.41%+77.52% 54.83B
+0.63%-0.53%-18.57%-14.50% 23.04B
-0.28%-4.09%+2.39%+387.96% 22.7B
-0.21%+0.84%+22.48%-7.92% 20.23B
0.00%+3.00%+27.41%-29.52% 17.83B
-0.97%+0.89%+37.28%+539.62% 15.65B
-6.69%-5.11%+166.00%+304.89% 15.24B
+0.27%-0.61%+25.65%+180.98% 14.03B
Average -1.24%-0.16%+37.93%+145.51% 24.07B
Weighted average by Cap. -1.28%+0.41%+37.52%+131.09%

Financials

2026 *2027 *
Net sales 234M 206M 191M 176M 330M 22.38B 336M 2.27B 889M 11.1B 879M 860M 38.34B 342M 300M 280M 257M 482M 32.71B 491M 3.32B 1.3B 16.22B 1.29B 1.26B 56.04B
Net income -10.96M -9.62M -8.96M -8.24M -15.45M -1.05B -15.71M -106M -41.6M -519M -41.15M -40.26M -1.79B 65.62M 57.58M 53.62M 49.32M 92.46M 6.27B 94.04M 636M 249M 3.11B 246M 241M 10.74B
Net Debt -20.97M -18.4M -17.14M -15.76M -29.55M -2B -30.05M -203M -79.58M -994M -78.72M -77.02M -3.43B -169M -148M -138M -127M -238M -16.15B -242M -1.64B -641M -8.01B -634M -621M -27.67B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
28/07/26 $1.465 -1.01% 3,201,715
27/07/26 $1.480 +4.23% 8,915,738
24/07/26 $1.420 -2.07% 3,292,732
23/07/26 $1.450 +2.84% 4,264,753
22/07/26 $1.410 -2.08% 5,693,370
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.480USD
Average target price
4.250USD
Spread / Average Target
+187.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock